-+ 0.00%
-+ 0.00%
-+ 0.00%

What Does Bristol Myers Squibb (BMY) Clinical Momentum Mean For Its Growth Story?

Simply Wall St·11/20/2026 06:14:15
Listen to the news
  • Bristol-Myers Squibb (NYSE:BMY) reported broad clinical momentum across hematology and central nervous system programs in November 2026.
  • At the 68th ASH Annual Meeting, the drugmaker presented five-year Breyanzi data in second-line large B-cell lymphoma, as well as new CELMoD and dual-targeting CAR T findings in multiple myeloma.
  • The pipeline update included preliminary Phase 3 KarXT results in Alzheimer’s psychosis, an Evotec protein degradation IND milestone, and a new Erasca trial in RAS-mutant cancers.
  • The five-year Breyanzi results and wider hematology and CNS push matter, but they are only one piece of the Bristol Myers Squibb story. We have also flagged 3 warning signs (1 major) for Bristol-Myers Squibb.

This burst of Bristol Myers Squibb clinical news is one example of how large pharma leans into similar long-duration themes as 53 AI infrastructure stocks.

NYSE:BMY Earnings & Revenue Growth as at Nov 2026
NYSE:BMY Earnings & Revenue Growth as at Nov 2026

Bristol-Myers Squibb, a US-based biopharma group with a market value of about $121.7b, focuses on discovering and marketing prescription treatments across oncology, hematology and central nervous system disorders. This makes the current wave of hematology and CNS trial activity especially relevant to its core franchise.

4 things going right for Bristol-Myers Squibb that this headline doesn't cover.

Clinical breadth reinforces the Bristol-Myers Squibb pipeline story, but does not solve the patent cliff problem

For Bristol-Myers Squibb, the cluster of Breyanzi, CELMoD, CAR T, KarXT, protein degradation and RAS-cancer updates supports the core narrative that a broad late stage portfolio can help offset pressure from aging blockbusters. It leans directly into the catalyst that calls for execution across oncology, neuroscience and protein degradation partnerships, while also speaking to the reward case that earnings grew 53.1% over the past year and the business pays a 4.32% dividend. What this busy data slate does not yet address is the major risk that earnings are forecast to decline by an average of 4.3% a year over the next three years as key patents roll off.

See how these catalysts shape Bristol-Myers Squibb's path to a $65.25 fair value.

The cleanest test of whether this clinical momentum is translating into a more durable business will be how quickly the new hematology and CNS assets progress into regulatory filings and labeled indications, especially the timing and scope of Phase 3 readouts and approvals for CELMoDs, next generation CAR T therapies and KarXT in Alzheimer’s psychosis through 2027.

Add Bristol-Myers Squibb to your Watchlist and get alerts as these catalysts play out.